Insufficient scRNA-seq data for expression of ALOXE3 at single-cell level.
Insufficient scRNA-seq data for expression of ALOXE3 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
skin | 81% | 6005.75 | 1473 / 1809 | 12% | 1.12 | 55 / 472 |
esophagus | 25% | 50.11 | 364 / 1445 | 60% | 5.65 | 110 / 183 |
brain | 68% | 136.54 | 1797 / 2642 | 10% | 0.17 | 69 / 705 |
tonsil | 0% | 0 | 0 / 0 | 76% | 3.89 | 34 / 45 |
breast | 22% | 17.32 | 102 / 459 | 31% | 0.94 | 342 / 1118 |
uterus | 2% | 5.14 | 4 / 170 | 41% | 2.32 | 186 / 459 |
bladder | 14% | 6.43 | 3 / 21 | 27% | 1.00 | 137 / 504 |
prostate | 31% | 21.38 | 75 / 245 | 9% | 0.13 | 46 / 502 |
ovary | 3% | 5.21 | 5 / 180 | 35% | 0.92 | 151 / 430 |
lung | 3% | 5.49 | 20 / 578 | 29% | 1.03 | 332 / 1155 |
pancreas | 5% | 4.28 | 16 / 328 | 24% | 0.50 | 42 / 178 |
stomach | 4% | 4.17 | 16 / 359 | 9% | 0.25 | 27 / 286 |
thymus | 1% | 0.89 | 9 / 653 | 10% | 0.15 | 58 / 605 |
intestine | 1% | 0.35 | 5 / 966 | 9% | 0.29 | 45 / 527 |
liver | 3% | 5.26 | 6 / 226 | 5% | 0.12 | 22 / 406 |
adrenal gland | 2% | 2.92 | 5 / 258 | 5% | 0.09 | 11 / 230 |
kidney | 4% | 5.37 | 4 / 89 | 2% | 0.08 | 20 / 901 |
heart | 3% | 4.00 | 28 / 861 | 0% | 0 | 0 / 0 |
adipose | 2% | 5.80 | 19 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 1% | 0.03 | 1 / 80 |
spleen | 1% | 1.27 | 3 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 1% | 0.60 | 8 / 929 | 0% | 0 | 0 / 0 |
blood vessel | 1% | 3.37 | 9 / 1335 | 0% | 0 | 0 / 0 |
muscle | 1% | 2.14 | 5 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0019233 | Biological process | sensory perception of pain |
GO_0035357 | Biological process | peroxisome proliferator activated receptor signaling pathway |
GO_0043651 | Biological process | linoleic acid metabolic process |
GO_0061436 | Biological process | establishment of skin barrier |
GO_0034440 | Biological process | lipid oxidation |
GO_0019372 | Biological process | lipoxygenase pathway |
GO_0046513 | Biological process | ceramide biosynthetic process |
GO_0006665 | Biological process | sphingolipid metabolic process |
GO_0019369 | Biological process | arachidonic acid metabolic process |
GO_0051122 | Biological process | hepoxilin biosynthetic process |
GO_0045444 | Biological process | fat cell differentiation |
GO_0005829 | Cellular component | cytosol |
GO_0106255 | Molecular function | hydroperoxy icosatetraenoate isomerase activity |
GO_0050486 | Molecular function | intramolecular hydroxytransferase activity |
GO_0005506 | Molecular function | iron ion binding |
GO_0051120 | Molecular function | hepoxilin A3 synthase activity |
GO_0106256 | Molecular function | hydroperoxy icosatetraenoate dehydratase activity |
GO_0005515 | Molecular function | protein binding |
GO_0016702 | Molecular function | oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen |
Gene name | ALOXE3 |
Protein name | Hydroperoxide isomerase ALOXE3 (Epidermis-type lipoxygenase 3) (Epidermal LOX-3) (e-LOX-3) (eLOX-3) (Hydroperoxy dehydratase ALOXE3) (Hydroperoxy icosatetraenoate dehydratase) (EC 4.2.1.152) (Hydroperoxy icosatetraenoate isomerase) (EC 5.4.4.7) Arachidonate lipoxygenase 3, isoform CRA_a (Hydroperoxide isomerase ALOXE3) |
Synonyms | hCG_31289 |
Description | FUNCTION: Non-heme iron-containing lipoxygenase which is atypical in that it displays a prominent hydroperoxide isomerase activity and a reduced lipoxygenases activity . The hydroperoxide isomerase activity catalyzes the isomerization of hydroperoxides, derived from arachidonic and linoleic acid by ALOX12B, into hepoxilin-type epoxyalcohols and ketones . In presence of oxygen, oxygenates polyunsaturated fatty acids, including arachidonic acid, to produce fatty acid hydroperoxides . In the skin, acts downstream of ALOX12B on the linoleate moiety of esterified omega-hydroxyacyl-sphingosine (EOS) ceramides to produce an epoxy-ketone derivative, a crucial step in the conjugation of omega-hydroxyceramide to membrane proteins . Therefore plays a crucial role in the synthesis of corneocytes lipid envelope and the establishment of the skin barrier to water loss . In parallel, it may have a signaling function in barrier formation through the production of hepoxilins metabolites . Also plays a role in adipocyte differentiation through hepoxilin A3 and hepoxilin B3 production which in turn activate PPARG (By similarity). Through the production of hepoxilins in the spinal cord, it may regulate inflammatory tactile allodynia (By similarity). . |
Accessions | ENST00000380149 ENST00000448843.7 [Q9BYJ1-1] J3KPH2 ENST00000318227.4 [Q9BYJ1-1] ENST00000380149.6 [Q9BYJ1-1] Q9BYJ1 |